January 30, 2015
President's 2016 budget proposes historic investment to combat antibiotic-resistant bacteria to protect public health.
"We now have a national strategy to combat antibiotic-resistant bacteria, to better protect our children and grandchildren from the reemergence of diseases and infections that the world conquered decade ago"
- President Barack Obama's remarks at the Global Health Security Agenda Summit, regarding the Executive Order to Combat Antibiotic Resistance, September 26, 2014.
January 27, 2015
The 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting will be held from April 25-28, 2015 in Copenhagen, Denmark. The meeting will feature a series of keynote lectures, symposia, educational workshops and meet-the-experts sessions on parallel tracks, covering the entire field of infectious diseases and clinical microbiology. Among the presentations will be:
Evaluating the induction potential of three antibiotics in the hamster Clostridium difficile infection model.
M. Pulse, T. Murphy, P. Nguyen, K. Peterson, J. Silva, J. Simecka, D. Valtierra, W. Weiss, S. Sayah-Jeanne, J. de Gunzburg
UNT Health Science Center, Fort Worth, TX & Dalvolterra, Paris, France
Efficacy evaluation of TP-271, a novel fluorocycline, in a neutropenic murine pneumonia model against susceptible and resistant gram-positive pathogens
W. Weiss, T. Murphy, M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, J. Silva, J. Simecka, J. Sutcliffe, T. Grossman
UNT Health Science Center, Fort Worth, TX & Tetraphase Pharmaceuticals, Watertown, MA
Synthetic novel host defense protein mime tics for the treatment of gram-negative bacterial infections
S. Ram, K. Menon, R. Scott, D. Weaver, K. Freeman, G. Tew, W. Weiss, W. DeGrado, K. Fadela, A. Kumar, D. Brennan, S. Holden
Fox Chase Chemical Diversity Center, Doylestown, PA & UNT Health Science Center, Fort Worth, TX
January 15, 2015
UNTHSC PreClinical Services to present at the SMI 17th Annual conference on SuperBugs & SuperDrugs, March 25-26, 2015 in London, UK.
The Changing Role of Academia in Drug Discovery
- Historical perspective of academic involvement in drug development
- Growth of the modern pharmaceutical industry and detachment from academia
- Downturn in antibacterial discovery and development and current needs
- Collaboration of industry and academia in drug discovery
- Novel partnering models to increase innovation
William Weiss, Director of PreClinical Services, UNT Health Science Center
July 3, 2014
The UNTHSC Pre-Clinical Services group will be in attendance at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington DC (September 5 - 9, 2014) and welcomes the opportunity to meet with current as well as prospective collaborators to discuss ongoing and future projects. If interested, please contact William Weiss (817-735-2111 or firstname.lastname@example.org) to arrange for a convenient day and time to meet.
In addition, please plan on attending the following presentations:
Poster Session 172 - New Spins on Protein Synthesis Inhibitors
Monday, Sept. 08, 2014; 11:00am - 1:00pm
Pharmacodynamic evaluation of TP-271, a novel fluorocycline, in a neutropenic murine lung model infected with Streptococcus pneumoniae - presented by Tim Murphy
Pharmacodynamics of the fluorocycline TP-271 in a neutropenic murine lung infection model with methicillin-resistant Staphylococcus aureus - presented by Bill Weiss
Slide Session 200 - Clostridium difficile: Pathogenesis, Immune Response and Therapy
Monday, Sept. 08, 2014; 4:00pm - 4:15pm
Epidemic Clostridium difficile ribotype 027 strains are more virulent than other non-epidemic strains in the hamster CDAD model - presented by Mark Pulse
April 24, 2014
The UNTHSC Pre-Clinical Services group will be attending the 24th ECCMID meeting in Barcelona, Spain from May 9-14 and welcomes the opportunity to meet with interested parties. Please contact William Weiss (817-735-2111 or email@example.com) to arrange for a convenient day and time to meet.
In addition, please stop by the following poster presentations:
Saturday - May 10th - 3:30pm: Poster P0112 - Ileal Dosing of Nisin and Miconazole Combination is Efficacious in the Hamster Clostridium difficile Associated Disease Model (Presented by Mark Pulse, Assistant Director UNTHSC Pre-Clinical Services).
Sunday - May 11th - 1:30pm: Poster 0804 - DAV131, an oral absorbent-based product, exerts dose-dependent protection of hamsters against moxifloxacin-induced Clostridium difficile lethal infection (Presented by DaVolterra in conjunction with UNTHSC).
March 1, 2014
SMI presents Superbugs & Superdrugs - A Focus on Antibacterials
May 5 - 6, 2014, London, UK
"Research and Development in Neglected Diseases" (presented by William Weiss, Director of UNTHSC Pre-Clinical Services)
- Overview and Clinical Relevance
- Current therapies and issues
- Why pursue research of neglected diseases?
- New efforts and treatment options
June 7, 2013
The UNTHSC Pre-Clinical Services group will be in attendance at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Denver, Colorado (September 10-13, 2013) and welcomes the opportunity to meet with current Sponsors as well as prospective collaborators to discuss ongoing and future projects. If interested, please contact William Weiss (817-735-2111 or firstname.lastname@example.org) to arrange for a convenient day and time to meet.
In addition, please plan on attending the following presentations by Mark Pulse, Assistant Director of the Pre-Clinical Services group:
Wednesday, Sept 11. - Slide Session 066 - Clostridium difficile: Pathogenesis
10:00 - 10:15 am : Dosing clindamycin before and after infection dramatically impacts disease outcome in the hamster Clostridium difficile-assoicated disease model
Thursday, Sept. 12 - Poster Session 143 - Antimicrobial Resistance and Immune Therapy
11:00am - 1:00 pm : Characterization of the programmed death 1 (PD1) and its ligand, PD-L1, in a murine cecal ligation model of sepsis
April 27, 2013
23rd ECCMID Meeting, Berlin, Germany
Oral Session - New Antibacterial agents
In vivo Efficacy of the novel monosulfactam BAL300072 alone and in combination with meropenem against clinically important gram-negative pathogens
William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
March 1, 2013
SMI Presents: Superbugs & Superdrugs - A Focus on Antibacterials
4th March to 5th March 2013, London, UK
AN UPDATE ON CURRENT ISSUES AND PROGRESS IN C. DIFFICILE DISEASE (CDAD)
William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
- A brief history and review
- The changing epidemiology and resistance development in CDAD
- Transmission, Virulence factors and clinical manifestations
- Surveillance, diagnosis and clinical testing
- Prevention, emerging therapies and potential for efficacy
November 12, 2012
UNTHSC Pre-Clinical Services (PCS) is pleased to announce the recent hire of Timothy Murphy who joins the group as Project Manager.
Tim comes to the group with 16 years experience in the drug discovery and pharmacology industry. He has previously held positions of increasing responsibility in ViviSource Laboratories, Arpida Inc., Enanta Pharmaceuticals and Wyeth Research. Tim brings with him extensive experience and expertise in the design and performance of anti-infective efficacy models: antibacterial and antiviral, pharmacology and oncology studies as well as PK/PD evaluations and vaccine discovery research. He has earned both B.S. and M.S. degrees in biology and has co-authored or presented numerous manuscripts and presentations.
UNTHSC PCS welcomes Tim and looks forward to the contributions that he will make along with expanding the expertise and scope of testing that the group has to offer to our Sponsors.
July 30, 2012
The UNTHSC Pre-Clinical Services group will be in attendance at the 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICCAC) in San Francisco, CA (September 9 - 12, 2012) and welcomes the opportunity to meet with current collaborators as well as prospective Sponsors to discuss ongoing and future research projects, utilizing our expertise to meet your R & D requirements. If interested, please contact William Weiss (817-725-2111 or email@example.com) to arrange for a convenient day and time to meet.
April 2, 2012
UNTHSC Pre-Clinical services, in conjunction with Affinium Pharmaceuticals, presented their findings on the effects of AFN-1252, a novel fatty acid biosynthesis inhibitor antibacterial agent, on the in vitro and in vivo expression of S. aureus virulence genes at the 22nd European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in London, UK.
Presentation Summary: (full details and time can be found on the ECCMID Congress website)
Poster P2058 - AFN-1252 Alters In Vitro and In Vivo Staphylococcus aureus Gene Expression and Reduces Bacterial Counts in a Mouse Granuloma Infection Model
M. E. Pulse1, N. Kaplan2, J. Parsons3, C. O. Rock3, M. Kukula1, P. Nguyen1, J. Pierce1, D. Valtierra1, W. J. Weiss1, J. W. Simecka1
1UNTHSC, Fort Worth, TX, 2Affinium Pharmaceuticals, Toronto, Canada, 3St. Jude Children’s Res. Hosp., Memphis, TN
Exposure of S. aureus cultures to AFN-1252 resulted in the anticipated up-regulation of genes involved in the FAS II pathway associated with the FapR regulon and the unpredicted down-regulation of several virulence genes that are controlled by the SaeRS two-component regulator. In the MG infection model, a single oral dose of AFN-1252 at 2 hours post-infection resulted in mean log10 CFU reductions of 2.9 - 3.1 in 24 - 48 hours after dosing. PK analysis of this fluid revealed that the relative exposure (AUC) of AFN-1252 in the granuloma fluid was 85% of the corresponding plasma levels, and qRT-PCR of S. aureus RNA extracted from granuloma fluid indicated that fabH expression was up-regulated and virulence factor expression was down-regulated following the single dose of AFN-1252. AFN-1252 was also dosed consecutively (2, 26, 50 hours) in the MG model, which maximally reduced granuloma-associated S. aureus counts by 5.3 log10 CFU within 72 hours of the first dose. AFN-1252 triggered the up-regulation of genes associated with the FASII pathway in S. aureus, and it simultaneously down-regulated virulence genes controlled by the SaeRS regulator. AFN-1252 not only altered S. aureus gene expression in the granuloma fluid, but it also therapeutically reduced the CFU counts in the fluid as well.